US Bancorp DE decreased its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA – Free Report) by 15.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,232 shares of the company’s stock after selling 3,290 shares during the quarter. US Bancorp DE’s holdings in Privia Health Group were worth $357,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Privia Health Group by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 11,003,989 shares of the company’s stock valued at $253,092,000 after acquiring an additional 51,317 shares during the period. Bell Bank increased its holdings in shares of Privia Health Group by 49.1% in the fourth quarter. Bell Bank now owns 27,758 shares of the company’s stock valued at $639,000 after purchasing an additional 9,143 shares during the period. Trust Point Inc. purchased a new position in shares of Privia Health Group in the fourth quarter worth about $585,000. Riverbridge Partners LLC lifted its holdings in shares of Privia Health Group by 8.7% during the fourth quarter. Riverbridge Partners LLC now owns 4,342,385 shares of the company’s stock worth $100,005,000 after purchasing an additional 348,852 shares during the period. Finally, International Assets Investment Management LLC lifted its holdings in shares of Privia Health Group by 2,721.7% during the fourth quarter. International Assets Investment Management LLC now owns 7,139 shares of the company’s stock worth $164,000 after purchasing an additional 6,886 shares during the period. Hedge funds and other institutional investors own 94.48% of the company’s stock.
Wall Street Analyst Weigh In
PRVA has been the subject of a number of recent research reports. Citigroup started coverage on shares of Privia Health Group in a research report on Monday, April 22nd. They set a “buy” rating and a $25.00 price target for the company. Evercore ISI reduced their target price on shares of Privia Health Group from $23.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, July 9th. Stifel Nicolaus lowered their price target on shares of Privia Health Group from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Barclays reduced their price objective on Privia Health Group from $22.00 to $19.00 and set an “equal weight” rating for the company in a research note on Monday, May 20th. Finally, Truist Financial lowered their target price on Privia Health Group from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, May 15th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.54.
Read Our Latest Report on PRVA
Insider Buying and Selling
In other news, Director Adam Boehler acquired 5,306 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was bought at an average cost of $16.50 per share, for a total transaction of $87,549.00. Following the purchase, the director now owns 5,773,158 shares in the company, valued at $95,257,107. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Privia Health Group news, EVP Thomas Bartrum sold 1,506 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $17.88, for a total value of $26,927.28. Following the transaction, the executive vice president now owns 102,356 shares in the company, valued at approximately $1,830,125.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adam Boehler bought 5,306 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were acquired at an average cost of $16.50 per share, with a total value of $87,549.00. Following the acquisition, the director now directly owns 5,773,158 shares of the company’s stock, valued at $95,257,107. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 293,235 shares of company stock worth $4,745,481 and sold 45,457 shares worth $827,810. Insiders own 14.20% of the company’s stock.
Privia Health Group Price Performance
Privia Health Group stock opened at $20.46 on Friday. The stock has a market capitalization of $2.44 billion, a PE ratio of 136.40, a price-to-earnings-growth ratio of 3.08 and a beta of 0.78. The business has a 50 day simple moving average of $17.55 and a 200-day simple moving average of $19.14. Privia Health Group, Inc. has a 12 month low of $15.92 and a 12 month high of $28.10.
Privia Health Group (NASDAQ:PRVA – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.03). The company had revenue of $415.24 million during the quarter, compared to analysts’ expectations of $435.07 million. Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. On average, equities research analysts anticipate that Privia Health Group, Inc. will post 0.2 EPS for the current fiscal year.
Privia Health Group Profile
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
See Also
Receive News & Ratings for Privia Health Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Privia Health Group and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
